STEM CELLS UNLOCKED
Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
Syntax’s proprietary Cellgorithm technology mimics human development to generate a wide diversity of functional cell types to enable new product opportunities.
HUMAN DEVELOPMENT
Sequential coordinated cues between embryo + mother
Fast and precise; any cell
Pre-programmed seqential regulation in the right order; one-time delivery
Mimics development & native function; fast; any cell
Reduced growth factor requirements; Cellgorithm differentiations use fewer media steps
The Syntax platform provides customizable, epigenetic instructions to program step-wise cellular differentiation processes
Syntax is a force multiplier for existing cell therapy programs by making discovery faster, less costly and scalable, while also enabling patient access and new product opportunities.
ACCELERATED
DISCOVERY
Cutting differentiation timelines from months to days translates to faster process optimization and preclinical studies, accelerating time to IND
pipeline
expansion
Wide diversity of cell types that maintain native function increases indication space and ability to address larger disease areas
enhanced
scalability
A shorter and more reliable differentiation process improves patient access, reduces manufacturing costs, and decreases variability, phenotype drift and supply risks
collaboration business model
Biopharma discovery partnerships structured with upfront R&D payments, milestone-based fees, and royalties, making Syntax capital-efficient, while also capturing significant downstream economics
“Efficiently differentiating our cells is our largest issue. The time and effort required are immense.”
- Cell Therapy Development Leader, Large Biopharma Organization
Our Investors
Leadership Team
John Craighead, PhD
CEO
Ryan Clarke, PhD
Cofounder, CTO
Brad Merrill, PhD
Cofounder, Head of Innovation
Niko Balanis, PhD
Cofounder, VP Data Sci & Molecular Bio
Nick Timmins, PhD
CSO
Board of Directors
Andy May, DPhil
Executive Chairman; Entrepreneur in Residence, DCVC Bio
Satoshi Konagai, MS, MBA
Investment Lead, Astellas Venture Management
John Flavin, MBA
Founder, CEO, Portal Innovations
John Craighead, PhD
Ryan Clarke, PhD
Scientific Advisors
Ryan Crisman, PhD
Cofounder, CTO Umoja Biopharma
Ryan Larson, PhD
Head of Translation, Umoja Biopharma
Matt MacDougall, MD, PhD
Scientific Cofounder, Immunology Physician, Stanford University
Alex Chavez, MD, PhD
Associate Professor, UCSD